Form 4: Maravai LifeSciences Director Luke Marker Acquires Restricted Stock Units

Director Luke Joseph Marker reports acquisition of restricted stock units in Maravai LifeSciences Holdings, Inc.

Summary

• On May 23, 2024, Luke Joseph Marker, a director of Maravai LifeSciences Holdings, Inc. (MRVI), acquired 20,645 shares of Class A Common Stock.
• These shares were granted as restricted stock units.
• The price of the transaction was $10.78 per share.
• Following the transaction, Marker beneficially owns 48,916 shares, held indirectly for the benefit of a GTCR-affiliated entity.
• The restricted stock units vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.
• Marker disclaims any pecuniary interest in the securities, as they are held on behalf of a GTCR-affiliated entity.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The acquisition of shares by a director could be seen as slightly positive, but the disclaimer of pecuniary interest tempers this.

Positives

• The acquisition of restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The restricted stock units vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Management Comments

• The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16.

Industry Context

This filing is a routine disclosure of a transaction by a company insider, which is common in the biotechnology and life sciences industry.

Comparison to Industry Standards

• Insider transactions are a common occurrence in publicly traded companies, including those in the life sciences sector.
• Similar transactions are regularly reported by executives and directors at companies like Thermo Fisher Scientific, Danaher Corporation, and Agilent Technologies.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a company director.

Key Dates